The latest biotech news

News and Trends 31 Aug 2022

Compound found in trees has potential to kill drug-resistant bacteria

Researchers say the naturally-occurring compound hydroquinine has bacterial killing activity against several microorganisms. Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers identify possible target for type of sporadic ALS

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

United BioPharma gets FDA approval for phase 2 HIV drug trial

Taiwan-headquartered United BioPharma (UBP) says the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of the study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal product for both localized and diffuse types of the disease by the European Medicines Agency (EMA). No systemic treatments have been approved for TGCT in […]

August 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Laverock Therapeutics created to develop next generation of programmable cell therapies

Laverock Therapeutics Ltd has been founded to develop a gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the U.K. company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of its senior management team. Laverock Therapeutics started out […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS

Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

Sanofi drops amcenestrant clinical development program

News and Trends 30 Aug 2022

Potential new cancer treatment target discovered by researchers in Sweden

A previously unknown mechanism that can control tumor growth in cultured cells and mice has been identified by researchers at the University of Gothenburg, Sweden. This discovery may potentially enable future development of new drugs against a range of cancer diseases. In a research article published in the journal Nature Communications, the Gothenburg scientists described […]

August 30, 2022 - 2 minutesmins - By Liza Laws

gastrointestinal disease heptares imperial2 1

News and Trends 30 Aug 2022

Bactolife receives $5M in new funding to address gut infections worldwide

Bactolife has received an investment of $5 million from The Bill & Melinda Gates Foundation to accelerate the use of its technology platform that develops binding proteins for gut infections. The news was announced today (August 30) that in line with the foundation’s charitable mission, the investment would help develop the binding proteins which the […]

August 30, 2022 - 2 minutesmins - By Liza Laws

News and Trends 30 Aug 2022

Scientists unravel mystery behind neurodegenerative disease protein

Scientists have unraveled the mystery behind the mechanism behind a type of protein that leads to a progressive nervous system disease. In a study, recently published in the journal Physical Chemistry Chemical Physics, the researchers say that the RNA-binding ‘fused in sarcoma’ (FUS) protein transitions between liquid and solid phases inside cells. The scientists from […]

August 30, 2022 - 4 minutesmins - By Liza Laws

News and Trends 30 Aug 2022

Artificial intelligence-based algorithm to be used for reporting of lymph node status in colon cancer

A collaboration looking at the development of an artificial intelligence (AI)-based digital pathology solution to detect cancer within lymph nodes from colorectal surgery cases has been announced today (August 30). Indica Labs, which works in quantitative digital pathology and image management solutions, has joined forces with The Industrial Centre for Artificial Intelligence Research in Digital […]

August 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Aug 2022

Hemophilia drug from Sanofi and Sobi has license application accepted for priority review by FDA

The Biologics License Application (BLA) for Efanesoctocog alfa, a drug to treat the rare and life-threatening blood disease, hemophilia A, has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Efanesoctocog alfa (BIVV001) is being developed and commercialized as part of a collaboration between Sanofi and Sobi was given the target […]

August 30, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Aug 2022

Vilya emerges to target disease biology

VILYA, Inc. (Vilya), a biotech company aiming to create a new class of medicines to precisely target disease biology, launched today. Vilya is co-founded by scientists from the Institute of Protein Design (IPD) led by David Baker, and ARCH Venture Partners. The company’s platform, powered by advanced machine learning, taps into uncharted chemical space to […]

August 29, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Compound found in trees has potential to kill drug-resistant bacteria

Researchers identify possible target for type of sporadic ALS

United BioPharma gets FDA approval for phase 2 HIV drug trial

Emactuzumab designated as an orphan medicinal product for TGCT in Europe

Laverock Therapeutics created to develop next generation of programmable cell therapies

Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS

Potential new cancer treatment target discovered by researchers in Sweden

Bactolife receives $5M in new funding to address gut infections worldwide

Scientists unravel mystery behind neurodegenerative disease protein

Artificial intelligence-based algorithm to be used for reporting of lymph node status in colon cancer

Hemophilia drug from Sanofi and Sobi has license application accepted for priority review by FDA

Vilya emerges to target disease biology

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!